UK markets close in 1 hour 42 minutes

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.48+0.10 (+1.07%)
As of 09:48AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.38
Open9.43
Bid9.32 x 100
Ask9.61 x 100
Day's range9.39 - 9.57
52-week range8.82 - 21.00
Volume22,478
Avg. volume593,923
Market cap1.512B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

    Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pip

  • GlobeNewswire

    Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

    On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi

  • GlobeNewswire

    Neumora Therapeutics to Participate in Upcoming Conferences in May

    WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in May: BofA Securities Healthcare Conference 2024: Members of management will participate in a fireside chat on Tuesday, May 14, 2024, at 1:00 PM ET (10:00 AM PT) in Las Vegas, NV.2024